Last updated on March 2020

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women


Brief description of study

Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy. Hormonal therapy typically consists of oral estradiol and spironolactone, which induce drug-metabolizing enzymes after prolonged administration. This study evaluates the bi-directional potential drug interaction between the antiretroviral drug, doravirine, when co-administered with estradiol and spironolactone.

Clinical Study Identifier: NCT04283656

Find a site near you

Start Over